This autumn Outcomes 2022: Extra corporations introduced their January-March quarter outcomes on Thursday. The businesses which declared their quarterly outcomes included Exide Industries Restricted, Borosil Renewables and Morepen Laboratories. Listed here are key highlights of the earnings reported by these corporations.
Exide This autumn Outcomes 2022: Battery firm reviews internet revenue of Rs 3,953 cr in This autumn
Battery producer Exide Industries on Thursday reported a consolidated internet revenue of Rs 3,953 crore for the fourth quarter ended March 2022.
The corporate had posted a internet revenue of Rs 320 crore within the January-March quarter of 2020-21 fiscal.
The battery maker accomplished the sale of its unit — Exide Life Insurance coverage Firm Ltd on January 1, 2022, leading to a acquire of Rs 4,694 crore.
Income from operations rose to Rs 3,523 crore within the fourth quarter as towards Rs 3,024 crore within the year-ago interval, Exide Industries mentioned in a regulatory submitting.
For the 12 months ended March 31, 2022, the corporate posted a consolidated internet revenue of Rs 4,357 crore. It was Rs 803 crore in FY 2021.
Income from operations stood at Rs 12,789 crore within the final monetary 12 months, as towards Rs 10,359 crore in 2020-21.
“The corporate was profitable in appreciably reducing fastened prices; nonetheless, this might not totally neutralise the inflationary affect of sharp and continued escalation in costs of inputs, coupled with runaway gas and freight prices, resulting in a decline in working margins,” Exide Industries MD & CEO Subir Chakraborty mentioned.
Decreasing of fastened prices took place from the daring initiatives undertaken in gross sales transformation and price compression methods, that are presently yielding good-looking outcomes, he added.
Beneath the newly shaped wholly-owned subsidiary, Exide Vitality Options, the corporate plans to set-up a multi-gigawatt hour lithium-ion cell manufacturing facility, Chakraborty mentioned.
“Unfold out throughout two standard cell chemistries and three cell codecs, this unit shall be uniquely positioned to cater to the varied necessities of consumers in India,” he added.
The corporate mentioned its board has declared an interim dividend of Rs 2 per share on the face worth of Re 1 every for the 12 months 2021-22.
Exide Industries shares ended at Rs 148 on the NSE on Thursday and had been up per cent from the Wednesday closing value.
Borosil Renewables This autumn Outcomes 2022: internet revenue dips to Rs 46.38 cr in March quarter
Borosil Renewables’ March 2022 quarter internet revenue fell to Rs 46.38 crore towards Rs 66.87 crore within the year-ago interval, primarily resulting from decrease revenues.
The overall revenue declined to Rs 182.33 crore within the quarter from Rs 196.90 crore a 12 months in the past, confirmed a regulatory submitting on Thursday.
Its internet revenue rose to Rs 165.84 crore in 2021-22 from Rs 89.64 crore in 2020-21. For FY22, the overall revenue elevated to Rs 664.73 crore from Rs 507.63 crore within the previous fiscal.
The corporate is engaged solely within the enterprise of manufacture of flat glass, which is a single phase when it comes to Indian Accounting Customary Working Segments (lnd AS-108).
shares ended at Rs on the NSE on Thursday and had been up per cent from the Wednesday closing value.
Morepen This autumn Outcomes 2022: internet drops 55% to Rs 12 cr
Drug agency Morepen Laboratories on Thursday mentioned its consolidated internet revenue declined by 55 per cent to Rs 12 crore for the fourth quarter ended March 2022.
The corporate had reported a internet revenue of Rs 27 crore within the January-March quarter of 2020-21 fiscal.
Complete revenue elevated to Rs 371 crore for the interval below assessment as towards Rs 291 crore within the fourth quarter of 2020-21 monetary 12 months, Morepen Laboratories mentioned in a regulatory submitting.
For the 12 months ended March 31, 2022, the drug agency reported a consolidated internet revenue of Rs 102 crore as in comparison with Rs 97 crore in FY 2021.
Complete revenue elevated to Rs 1,557 crore in the course of the interval below assessment. It was Rs 1,200 crore within the year-ago interval.
“The corporate has been capable of broaden its market share and grown in all enterprise segments and expects to extend its profitability parameters within the subsequent few quarters as soon as the provision disruptions are normalised, which have resulted in elevated enter prices,” Morepen Laboratories Chairman and Managing Director Sushil Suri famous.
The corporate continues to spend money on creating new markets and launch new merchandise to succeed in an increasing number of clients, he added.
He additional mentioned: “Now we have bought shareholder’s approval for the conversion of financial institution’s desire shares into fairness capital, which is underway, whereas we watch for the regulatory approvals. It is going to be a giant milestone for the corporate, as soon as the method is accomplished.”
Morepen shares ended at Rs 42.70 on the NSE on Thursday and had been down over 11 per cent from the Wednesday closing value.
With Inputs from PTI
:max_bytes(150000):strip_icc()/Health-GettyImages-1190344849-fa128f3151504835963cac1e35b1df27.jpg "PEP, Supportive Care, and More")
